FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm may need to refile NDA for mobility-boosting Fampridine-SR.
You may also be interested in...
Chelsea Vows To Resolve Latest Regulatory Woes With Northera Quickly
Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.
Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.
Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.